AHA 2017:中国学者:预测AF患者1年缺血性卒中及血栓栓塞的风险模型——中国AF注册登记研究

2017-11-23 佚名 国际循环

首都医科大学附属北京安贞医院杜昕教授研究团队创建了一种可更好地预测AF患者1年血栓栓塞事件(包括缺血性卒中、短暂性脑缺血发作及其他血栓栓塞事件)风险的新模型。

众所周知,临床实践中医生在为心房颤动(AF)患者制定抗凝决策时需准确预测缺血性卒中风险。美国-阿纳海姆时间2017年11月14日,AHA 2017科学年会上发布的一项中国研究,首都医科大学附属北京安贞医院杜昕教授研究团队创建了一种可更好地预测AF患者1年血栓栓塞事件(包括缺血性卒中、短暂性脑缺血发作及其他血栓栓塞事件)风险的新模型(摘要号:19255)。

研究者杜昕教授等对中国AF注册登记(CAFR)研究中受试患者的分析显示,随访1年共计172例患者发生了血栓栓塞事件。其创建的新风险预测模型(CAFR模型)共计纳入9个预测因素(见表1),其中7个预测因素(年龄、性别、既往血栓栓塞病史、充血性心力衰竭、空腹血糖、高血压血管疾病)为强制变量,2个为选择变量(低体重及颅内出血)。分析发现,针对CAFR队列,CAFR模型预测血栓栓塞事件的平均C统计值为(0.71±0.02),显著高于Framingham AF卒中预测评分(0.66±0.02)和CHA2DS2-VASc评分(0.68±0.02)。CAFR模型对血栓栓塞事件的预测能力见(图1)。



表1. 多因素Logistic回归模型所示的可预测AF患者血栓栓塞事件的变量



图1. CAFR模型预测血栓栓塞事件的C统计值

该研究提示:与既往AF风险评分相比,CAFR风险模型能更好地预测AF患者的1年血栓栓塞事件,有助于改善AF患者的抗凝决策。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1892980, encodeId=2f861892980ae, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Jul 11 09:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779447, encodeId=4c021e794471a, content=<a href='/topic/show?id=09a8208303' target=_blank style='color:#2F92EE;'>#AF患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2083, encryptionId=09a8208303, topicName=AF患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Tue Jul 17 15:45:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806203, encodeId=8a8018062039a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 21 20:45:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264450, encodeId=6a48264450b8, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Nov 26 09:30:11 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267633, encodeId=3f57126e6335c, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457388, encodeId=0e66145e3884f, content=<a href='/topic/show?id=36ea100885d0' target=_blank style='color:#2F92EE;'>#风险模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100885, encryptionId=36ea100885d0, topicName=风险模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18b75898745, createdName=wjywjy, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556790, encodeId=aaa01556e90d1, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1892980, encodeId=2f861892980ae, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Jul 11 09:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779447, encodeId=4c021e794471a, content=<a href='/topic/show?id=09a8208303' target=_blank style='color:#2F92EE;'>#AF患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2083, encryptionId=09a8208303, topicName=AF患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Tue Jul 17 15:45:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806203, encodeId=8a8018062039a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 21 20:45:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264450, encodeId=6a48264450b8, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Nov 26 09:30:11 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267633, encodeId=3f57126e6335c, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457388, encodeId=0e66145e3884f, content=<a href='/topic/show?id=36ea100885d0' target=_blank style='color:#2F92EE;'>#风险模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100885, encryptionId=36ea100885d0, topicName=风险模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18b75898745, createdName=wjywjy, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556790, encodeId=aaa01556e90d1, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
    2018-07-17 zhmscau
  3. [GetPortalCommentsPageByObjectIdResponse(id=1892980, encodeId=2f861892980ae, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Jul 11 09:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779447, encodeId=4c021e794471a, content=<a href='/topic/show?id=09a8208303' target=_blank style='color:#2F92EE;'>#AF患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2083, encryptionId=09a8208303, topicName=AF患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Tue Jul 17 15:45:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806203, encodeId=8a8018062039a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 21 20:45:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264450, encodeId=6a48264450b8, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Nov 26 09:30:11 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267633, encodeId=3f57126e6335c, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457388, encodeId=0e66145e3884f, content=<a href='/topic/show?id=36ea100885d0' target=_blank style='color:#2F92EE;'>#风险模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100885, encryptionId=36ea100885d0, topicName=风险模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18b75898745, createdName=wjywjy, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556790, encodeId=aaa01556e90d1, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1892980, encodeId=2f861892980ae, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Jul 11 09:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779447, encodeId=4c021e794471a, content=<a href='/topic/show?id=09a8208303' target=_blank style='color:#2F92EE;'>#AF患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2083, encryptionId=09a8208303, topicName=AF患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Tue Jul 17 15:45:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806203, encodeId=8a8018062039a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 21 20:45:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264450, encodeId=6a48264450b8, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Nov 26 09:30:11 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267633, encodeId=3f57126e6335c, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457388, encodeId=0e66145e3884f, content=<a href='/topic/show?id=36ea100885d0' target=_blank style='color:#2F92EE;'>#风险模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100885, encryptionId=36ea100885d0, topicName=风险模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18b75898745, createdName=wjywjy, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556790, encodeId=aaa01556e90d1, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
    2017-11-26 大爰

    学习了谢谢分享!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1892980, encodeId=2f861892980ae, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Jul 11 09:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779447, encodeId=4c021e794471a, content=<a href='/topic/show?id=09a8208303' target=_blank style='color:#2F92EE;'>#AF患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2083, encryptionId=09a8208303, topicName=AF患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Tue Jul 17 15:45:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806203, encodeId=8a8018062039a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 21 20:45:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264450, encodeId=6a48264450b8, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Nov 26 09:30:11 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267633, encodeId=3f57126e6335c, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457388, encodeId=0e66145e3884f, content=<a href='/topic/show?id=36ea100885d0' target=_blank style='color:#2F92EE;'>#风险模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100885, encryptionId=36ea100885d0, topicName=风险模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18b75898745, createdName=wjywjy, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556790, encodeId=aaa01556e90d1, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
    2017-11-25 zhaohui6731
  6. [GetPortalCommentsPageByObjectIdResponse(id=1892980, encodeId=2f861892980ae, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Jul 11 09:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779447, encodeId=4c021e794471a, content=<a href='/topic/show?id=09a8208303' target=_blank style='color:#2F92EE;'>#AF患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2083, encryptionId=09a8208303, topicName=AF患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Tue Jul 17 15:45:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806203, encodeId=8a8018062039a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 21 20:45:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264450, encodeId=6a48264450b8, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Nov 26 09:30:11 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267633, encodeId=3f57126e6335c, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457388, encodeId=0e66145e3884f, content=<a href='/topic/show?id=36ea100885d0' target=_blank style='color:#2F92EE;'>#风险模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100885, encryptionId=36ea100885d0, topicName=风险模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18b75898745, createdName=wjywjy, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556790, encodeId=aaa01556e90d1, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1892980, encodeId=2f861892980ae, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Jul 11 09:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779447, encodeId=4c021e794471a, content=<a href='/topic/show?id=09a8208303' target=_blank style='color:#2F92EE;'>#AF患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2083, encryptionId=09a8208303, topicName=AF患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Tue Jul 17 15:45:00 CST 2018, time=2018-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806203, encodeId=8a8018062039a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 21 20:45:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264450, encodeId=6a48264450b8, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Nov 26 09:30:11 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267633, encodeId=3f57126e6335c, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457388, encodeId=0e66145e3884f, content=<a href='/topic/show?id=36ea100885d0' target=_blank style='color:#2F92EE;'>#风险模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100885, encryptionId=36ea100885d0, topicName=风险模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18b75898745, createdName=wjywjy, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556790, encodeId=aaa01556e90d1, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Sat Nov 25 11:45:00 CST 2017, time=2017-11-25, status=1, ipAttribution=)]
    2017-11-25 zhyy93

相关资讯

AHA2017:RE-DUAL PCI亚组分析:房颤患者应用新型口服抗凝药/氯吡格雷双联抗栓治疗更安全有效

2017年美国心脏协会(AHA)科学年会,在抗栓late-breaking重磅研究专题中,RE-DUAL PCI主要研究者之一、瑞典乌普萨拉大学Jonas Oldgren教授报道了最新亚组分析结果。

JAHA:白细胞端粒长度与房颤发生风险有关吗?

在该适当大小的以社区为基础的队列中,研究人员没有发现LTL与房颤发生风险之间存在显著关联的证据。

PLoS One:房颤患者心源性猝死的预测指标

在ARIC研究中,与非突发性CV死亡无关的SCD预测因子包括BMI增加,心率增加和低白蛋白。

Circulation:房颤的遗传易感性、临床危险因素负担和终生风险分析!

在这项社区为基础的队列中,房颤的终生风险为37%。多基因房颤风险的估计是可行的,加上临床危险因素负担可以解释长期房颤风险的严重梯度。

JACC:NOACs相比华法林对房颤患者肾脏影响更小

终身口服抗凝药,比如华法林和非维生素K拮抗剂口服抗凝药(NOAC),被推荐用来预防房颤患者卒中的发生,最新的研究认为在肾功能影响方面NOACs可能比华法林更佳。本研究的目的旨在比较评估四种口服抗凝药(阿哌沙班、达比加群、利伐沙班和华法林)对四种肾脏预后结局的影响:肾小球滤过率(eGFR)下降≥30%、血清肌酐水平加倍、急性肾损伤(AKI)和肾衰。本研究纳入了2010年十月至2016年四月开始口服抗

JACC:房颤的类型对心衰患者预后的影响研究

房颤在心衰患者中较常见,但不同类型的房颤的预后如何尚未阐明。本研究的目的旨在评估射血分数降低心衰患者不同房颤类型(阵发性、持续性或永久性、新发型)的预后结局。本研究共纳入15415名患者,其中有5481名(35.6%)患者有房颤病史,1645名(30%)患者为阵发性房颤。与无房颤的患者相比,伴有阵发性房颤患者的心源性死亡(HR: 1.20; 95%  [CI]: 1.09 - 1.32;